The Metabolic Acidosis market report also offers comprehensive insights into the Metabolic Acidosis market size, share, Metabolic Acidosis epidemiology, emerging therapies, market drivers and barriers, ongoing clinical trials, key collaboration in the space, market uptake by key therapies and companies actively pushing Metabolic Acidosis market size growth forward.
Some of the key highlights from the Metabolic Acidosis Market Insights Report:
In February 2025, Milla Pharmaceuticals, via its U.S. subsidiary, obtained FDA approval for a generic formulation of Hospira’s THAM Solution Tromethamine Injection 18GM/500ml, designed for the prevention and treatment of metabolic acidosis.
In 2023, the U.S. market for metabolic acidosis therapies was valued at approximately USD 117.6 million, accounting for around 70% of the total market across the seven major markets (7MM).
Metabolic acidosis is a condition marked by a drop in blood pH due to excess acid accumulation or a loss of bicarbonate, disrupting the body’s acid-base balance. It can arise from various underlying conditions, including kidney failure, diabetic ketoacidosis, lactic acidosis, and prolonged diarrhea, which depletes bicarbonate levels.
Across the 7MM, there were about 1.7 million diagnosed cases of metabolic acidosis in 2023. In the United States, approximately 850,000 of these cases were linked to chronic kidney disease (CKD) stages 3 to 5, while the rest were associated with diagnosed cases of distal renal tubular acidosis (dRTA), both inherited and acquired.
Males accounted for nearly 55% of all metabolic acidosis cases, a trend attributed to the higher prevalence of underlying conditions such as CKD and diabetes in men, both of which are major contributors to the disease.
In 2023, treated cases of dRTA, both inherited and acquired, made up less than 1.5% of all treated metabolic acidosis cases in the U.S. This is largely due to the rarity of dRTA as a cause of metabolic acidosis, especially in comparison to more common conditions like diabetic ketoacidosis and lactic acidosis.
Currently, no drugs have received direct FDA approval specifically for metabolic acidosis. However, several medications are available to manage its symptoms and underlying causes, offering indirect treatment options for patients.
The metabolic acidosis treatment pipeline remains limited, with only a few companies actively advancing drug candidates through clinical trials. One notable therapy in development is Zagociguat by Tisento Therapeutics, which is currently in Phase II trials.
Several key pharmaceutical companies, including Tisento Therapeutics, Tricida, Advicenne Pharma, and others, are developing novel products to improve the Metabolic Acidosis treatment outlook.
Metabolic Acidosis therapies are Zagociguat, and others.
As per DelveInsight analysis, the Metabolic Acidosis market is anticipated to witness growth at a considerable CAGR
Strategise your business goals by understanding market dynamics @ Metabolic Acidosis Market Landscape
Metabolic Acidosis Overview
Metabolic acidosis is a condition in which blood pH decreases due to an excess accumulation of acid or a loss of bicarbonate, disrupting the body’s acid-base balance. This imbalance can arise from various causes, such as kidney failure, diabetic ketoacidosis, lactic acidosis, or prolonged diarrhea, which depletes bicarbonate reserves. When metabolic acidosis develops, the body’s buffering mechanisms become overwhelmed, leading to a drop in blood pH below the normal range (7.35-7.45), creating a more acidic environment. It is classified into high anion gap acidosis or normal anion gap acidosis, depending on the underlying cause and biochemical markers. Diagnosis starts with clinical suspicion, particularly in individuals with conditions like kidney disease, diabetes, or significant fluid loss. Blood tests are crucial for confirming the diagnosis, with an arterial blood gas (ABG) test measuring pH, partial pressure of carbon dioxide (PaCO2), and bicarbonate (HCO3-) levels. The anion gap, derived from serum electrolyte levels (Na+, Cl-, HCO3-), helps identify the cause of acidosis. A high anion gap indicates the presence of unmeasured anions, commonly associated with conditions such as diabetic ketoacidosis or lactic acidosis, while a normal anion gap suggests bicarbonate loss, as seen in cases like diarrhea or renal tubular acidosis.
Do you know the treatment paradigms for different countries? Download our Metabolic Acidosis Market Sample Report
Metabolic Acidosis Epidemiology Insights
In 2023, an estimated 1.7 million cases of metabolic acidosis were identified across the seven major markets (7MM). Among these, approximately 850,000 cases in the United States were associated with metabolic acidosis in individuals with chronic kidney disease (CKD) stages 3 to 5. The remaining cases were linked to diagnosed instances of distal renal tubular acidosis (dRTA), including both inherited and acquired forms.
Metabolic Acidosis Epidemiology Segmentation
DelveInsight’s Metabolic Acidosis market report is prepared on the basis of epidemiology model. It offers comprehensive insights to the Metabolic Acidosis historical patient pools and forecasted Metabolic Acidosis patients. The report provides in-depth data of various subtypes and for the same epidemiology is segmented further. The Metabolic Acidosis Market report proffers epidemiological analysis for the study period 2020-34 in the 7MM segmented into:
Metabolic Acidosis Prevalence
Age-Specific Metabolic Acidosis Prevalence
Gender-Specific Metabolic Acidosis Prevalence
Diagnosed and Treatable Cases of Metabolic Acidosis
Visit for more @ Metabolic Acidosis Epidemiological Insights
Metabolic Acidosis Market Outlook
The metabolic acidosis market varies across major global regions, influenced by differences in demand and healthcare infrastructure. In 2023, the market for metabolic acidosis treatments showed notable differences in size and growth potential among the seven major markets (7MM). The United States dominated the market, reaching approximately USD 117.6 million, while European countries, including Germany, France, Italy, Spain, and the UK, displayed varying market sizes.
In 2023, the U.S. market for metabolic acidosis treatments reached around USD 117.6 million, accounting for approximately 70% of the total market across the seven major markets (7MM). This dominant share highlights the United States as the leading market, driven by its advanced healthcare infrastructure and strong demand for effective therapies.
Among the EU4 countries and the UK, Germany held the largest market share for metabolic acidosis, valued at USD 9.1 million. This solidifies Germany’s position as a key player in the European market, reflecting its well-developed healthcare system and commitment to innovative treatment solutions.
Metabolic Acidosis Emerging Therapies
Zagociguat: Tisento Therapeutics
Metabolic Acidosis Key Companies
Tisento Therapeutics, Tricida, Advicenne Pharma, and others
For more information, visit Metabolic Acidosis Market Analysis, Patient Pool, and Emerging Therapies
Scope of the Metabolic Acidosis Market Report:
11 Years Forecast
7MM Coverage
Descriptive overview of Metabolic Acidosis, causes, signs and symptoms, diagnosis, treatment
Comprehensive insight into Metabolic Acidosis epidemiology in the 7MM
Metabolic Acidosis marketed and emerging therapies
Metabolic Acidosis companies
Metabolic Acidosis market drivers and barriers
Table of Contents:
1 Metabolic Acidosis Market Key Comprehensive Insights
2 Metabolic Acidosis Market Report Introduction
3 Competitive Intelligence Analysis for Metabolic Acidosis
4 Metabolic Acidosis Market Analysis Overview at a Glance
5 Executive Summary of Metabolic Acidosis
6 Metabolic Acidosis Epidemiology and Market Methodology
7 Metabolic Acidosis Epidemiology and Patient Population
8 Metabolic Acidosis Patient Journey
9 Metabolic Acidosis Treatment Algorithm, Metabolic Acidosis Current Treatment, and Medical Practices
10 Key Endpoints in Metabolic Acidosis Clinical Trials
11 Metabolic Acidosis Marketed Therapies
12 Metabolic Acidosis Emerging Therapies
13 Metabolic Acidosis: 7 Major Market Analysis
14 Attribute analysis
15 Access and Reimbursement Overview of Metabolic Acidosis
16 Metabolic Acidosis Market Key Opinion Leaders Reviews
18 Metabolic Acidosis Market Drivers
19 Metabolic Acidosis Market Barriers
20 SWOT Analysis
21 Disclaimer
22 DelveInsight Capabilities
23 About DelveInsight
Related Reports:
Metabolic Acidosis Epidemiology 2034
DelveInsight’s “Metabolic Acidosis – Epidemiology Forecast to 2034” report delivers an in-depth understanding of the disease, historical and forecasted Metabolic Acidosis epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Metabolic Acidosis Pipeline 2024
“Metabolic Acidosis Pipeline Insights, 2024” report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Metabolic Acidosis market. A detailed picture of the Metabolic Acidosis pipeline landscape is provided, which includes the disease overview and Metabolic Acidosis treatment guidelines.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Kritika RehaniEmail: Send EmailPhone: +14699457679Address:304 S. Jones Blvd #2432 City: Las VegasState: NevadaCountry: United StatesWebsite: https://www.delveinsight.com/
